Tvardi Therapeutics, Inc.
TVRD
$1.85
-$0.09-4.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.29% | 55.60% | 38.04% | -12.38% | -- |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 131.11% | -242.02% | -349.92% | -1,187.43% | -- |
| Change in Net Operating Assets | -114.81% | -6.00% | -94.12% | 276.62% | -- |
| Cash from Operations | 0.06% | 0.86% | -28.37% | -17.82% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 200.17% | 153.06% | -- | -- | -- |
| Cash from Investing | 200.17% | 153.06% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -74.53% | 17,533.33% | 10,540.00% | 10,520.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -102.01% | 917.36% | 1,801.53% | 149,257.14% | -- |
| Cash from Financing | -100.64% | -4.28% | -15.91% | 552,444.44% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -207.53% | 214.50% | -225.13% | 162.30% | -- |